Minkon Biotechnology

Minkon Biotechnology, also known as Guangzhou Mingkang Biotechnology, is a clinical-stage biopharmaceutical company based in China that specializes in the development of recombinant protein therapeutics for cardiovascular and cerebrovascular diseases. The company's flagship product, Mingfule (rhTNK-tPA), is a third-generation thrombolytic agent that has been approved in China for the treatment of acute myocardial infarction. Minkon is currently advancing Mingfule through Phase 3 clinical trials for acute ischemic stroke and is also exploring its utility in pulmonary embolism. In 2020, the company was acquired by Tibet Rhodiola Pharmaceutical Holding, which has since integrated Minkon's R&D and manufacturing expertise into its portfolio to drive the commercialization of its thrombolytic pipeline. The company maintains a strong focus on protein engineering and large-scale biologics manufacturing.